Patent ID: 8921057

Claim:
A method for judging a relapse risk of breast cancer, comprising: measuring an activity value and expression level of CDK1 contained in a cancer tissue obtained from a breast cancer patient and an activity value and expression level of CDK2 contained in the cancer tissue; obtaining a ratio of a CDK2 specific activity value versus a CDK1 specific activity value by the following expression: the ratio =(the specific activity value of CDK2 contained in the cancer tissue/(the specific activity value of CDK1 contained in the cancer tissue) ={(the activity value of CDK2 contained in the cancer tissue)/(the expression level of CDK2 contained in the cancer tissue)}/{(the activity value of CDK1 contained in the cancer tissue)/(the expression level of CDK1 contained in the cancer tissue)}; comparing the obtained ratio with a threshold value; and wherein the threshold value is determined by ranking ratio values of CDK2 specific activity values versus CDK1 specific activity values from a population of breast cancer patients, from lowest value to highest value, and setting a median value classifying the breast cancer patients into a low relapse group and a high relapse group as the threshold value; and judging high relapse risk when the obtained ratio is equal to or higher than the threshold value.